Private Label Tranexamic & Salicylic Acid Body Serum

Minimum order quantities for private label tranexamic acid body serums — especially those that also include salicylic acid — typically start at 100 to 500 units at the pilot or startup scale. This range is available from smaller boutique contract manufacturers and specialty cosmetic labs that cater to indie founders and DTC brands. Mid-tier manufacturers, who often offer more sophisticated filling equipment and more robust stability programs, generally set their floor between 500 and 2,500 units. Larger contract manufacturers working with retail chains or high-volume e-commerce brands usually require 2,500 to 10,000+ units per SKU. What actually moves the MOQ floor? Several factors. First, raw material purchasing: tranexamic acid is not a commodity ingredient. At small batch sizes, your manufacturer may be buying it in quantities that raise their per-unit raw material cost substantially, and some will absorb that by setting a higher minimum rather than a higher unit price. Second, batch size relative to equipment: most filling lines have a practical minimum batch size — often 20 to 50 kilograms — meaning anything below that number is essentially a custom run with a setup cost that gets amortized across fewer units. Third, formula complexity: a two-active formula with tight pH requirements needs more QC checkpoints, which takes technician time that is again spread across the total order. If your target MOQ is at or below 250 units, your best path is to look specifically for labs marketing themselves to indie brands, or to reach out through platforms like AJ Cosmo Labs where you can filter manufacturers who explicitly offer low-MOQ cosmetic contract manufacturing. It also helps to be flexible on packaging — a stock pump bottle with a custom label is far easier to produce at 200 units than a fully custom airless component. One common mistake first-timers make is accepting an MOQ quoted over the phone without confirming whether it includes packaging. Some manufacturers quote the MOQ for bulk formula only, then apply a separate (and often higher) minimum for the fill-and-label step. Always ask for a single all-in MOQ that covers formula, fill, label application, and outbound inspection. For EU-based brands, note that some European CPSR (Cosmetic Product Safety Report) assessors want to see at least a 12-week accelerated stability study before signing off, which some low-MOQ manufacturers skip to keep costs down. Verify this is in scope before signing. For small runs under 500 units, expect per-unit costs in the $9–$14 range for a 100–150 mL fill. That cost comes down meaningfully at 1,000+ units, where you'll often land in the $6–$9 band.

The total development timeline for a private label salicylic acid body serum — particularly one that also includes tranexamic acid — runs 8 to 16 weeks from the point you engage a contract manufacturer to the point your first production run is filled, labeled, and ready to ship. That range is wide because several stages can compress or expand depending on how prepared you are and how complex your formula is. Here is the typical stage-by-stage breakdown. Weeks 1–2: brief intake and formula scoping. Your cosmetic chemist or contract manufacturer reviews your spec sheet, asks clarifying questions about target actives and concentrations, skin feel preferences, fragrance-free vs. fragranced, fill size, and packaging. The more complete your brief, the faster this moves. Weeks 2–5: prototype development. The lab formulates one or more prototypes, balances the pH around both actives, and tests basic physical stability. You receive samples for sensory evaluation. Weeks 5–8: revision cycles. Most founders need one to three rounds of adjustments — tweaking texture, active concentrations, or scent. Each round adds roughly one to two weeks. Weeks 8–10: stability and safety testing initiation. Accelerated stability (45°C / 75% relative humidity) is set up simultaneously with consumer safety review. Note that a full 12-week accelerated stability readout will not be complete before your launch, so many brands launch on a preliminary stability pass and continue monitoring. Weeks 10–14: formula lock and production planning. Once you approve the formula, the manufacturer orders production-quantity raw materials (TXA can have a 2–4 week supplier lead time), schedules the fill line, and produces your batch. Weeks 14–16: QC, label application, and outbound. Finished goods inspection, label check, and shipment to your warehouse or 3PL. What extends this timeline most often: late-stage formula changes after you've already approved packaging (forces a compatibility re-check), custom packaging components with their own lead times (airless pumps from overseas can add 4–6 weeks), or slow response times between you and the manufacturer on approvals. What compresses it: using a stock formula from the manufacturer's existing library as a starting base (cuts prototype time to 1–2 weeks), pre-selecting packaging before formula lock, and working with a manufacturer who has TXA in-stock as a standard raw material. If your salicylic acid concentration is exactly 2% leave-on, the FDA classifies this as an OTC drug, which triggers additional regulatory steps — including a Drug Facts panel and adherence to 21 CFR Part 330 monograph requirements — that can add 2–4 weeks of documentation work. Using AJ Cosmo Labs to post your brief and field responses from multiple manufacturers simultaneously means you can do supplier selection in parallel with packaging research, shaving meaningful time off the front end of this process.

Whether a salicylic acid body serum is regulated as a cosmetic or an OTC drug in the United States depends almost entirely on the concentration and the product claims you make. The FDA's OTC drug monograph system (21 CFR Part 333 for anti-dandruff, 21 CFR Part 330 for acne) is the governing framework here, and salicylic acid sits inside both. For leave-on body products making acne claims, salicylic acid is an FDA-recognized OTC active ingredient at concentrations of 0.5% to 2%. If your formula hits exactly 2% SA in a leave-on body serum and you make any acne-related claim on the label or marketing materials — things like 'clears body acne,' 'reduces breakouts,' 'unclogs pores' — the product is an OTC drug. That means it requires a Drug Facts panel formatted to FDA specifications, it must follow the OTC monograph's directions and warnings, and your manufacturing facility must comply with pharmaceutical-grade cGMPs (21 CFR Parts 210/211), not just cosmetic GMPs. If you formulate at, say, 1.5% SA and make no drug claims — instead positioning the serum around 'smooth skin texture' or 'exfoliation' without referencing acne — you are operating as a cosmetic under 21 CFR Part 701. This is a much lighter regulatory burden: no Drug Facts panel, no drug-facility registration requirement, and standard cosmetic labeling rules apply. The critical mistake many indie founders make is launching at 2% SA with cosmetic-only labeling, then making acne claims in their Instagram captions or website copy. The FDA reviews marketing materials holistically — off-label digital claims can cause an otherwise compliant cosmetic label to be viewed as an unapproved new drug. For the EU, salicylic acid in rinse-off products is permitted at up to 3% as a cosmetic ingredient under Annex III of EC Regulation 1223/2009, and in leave-on products at up to 2%. Leave-on products must carry the warning 'Contains Salicylic Acid' and are not recommended for use by children under 3. There is no equivalent to the US OTC drug framework in the EU — claims are governed by cosmetic claim substantiation rules (Regulation 655/2013). Transexamic acid has no specific regulatory restriction in either the US or EU at cosmetic use concentrations (typically 1–3%), and is classified as a cosmetic ingredient in both markets, making the regulatory risk profile of a TXA + SA serum largely driven by the SA concentration and claims strategy. A cosmetic chemist or regulatory consultant should review your label and claims before you go to production. Many cosmetic contract manufacturers accessible through AJ Cosmo Labs have in-house regulatory teams or preferred consultants who can flag these issues early.

The total landed cost of private labeling a tranexamic acid serum — including formula development, raw materials, filling, packaging, and labeling — depends on order volume, active concentrations, and packaging choices, but here are realistic numbers you can plan around. At the pilot scale of 100–500 units in a 100–150 mL fill, expect a total per-unit cost of $9–$14. This includes the filled and labeled finished good but typically excludes formula development fees (which are usually billed separately as a one-time NRE, or non-recurring engineering, charge of $500–$2,500 depending on complexity) and stability testing ($800–$2,500 depending on scope). At the growth scale of 500–2,500 units, per-unit cost drops to roughly $6–$9 as raw material purchasing improves and the fixed fill-line setup cost is spread over more units. At scale of 2,500–10,000+ units, you're typically in the $4–$6 range. What drives cost up within any given MOQ band? Tranexamic acid is the dominant raw material cost driver — pharmaceutical-grade TXA runs roughly $80–$180 per kilogram depending on supplier and origin, and at a 3% inclusion in a 100 mL serum, you're using about 3 grams per unit, or $0.24–$0.54 in raw TXA cost alone. At scale that's manageable, but at 100 units it's a higher share of total BOM (bill of materials) cost. Salicylic acid is far cheaper — typically $5–$20 per kilogram — so it adds minimal BOM cost. Airless pump packaging adds $0.50–$1.50 per unit versus a standard lotion pump. Custom labels with spot UV or foil finishes add $0.30–$0.80 per unit versus a simple digital print. Formula development fees: some manufacturers waive development fees if you commit to a minimum production volume upfront. Others charge a flat $1,000–$2,500 for a custom formula starting from scratch. If you select an existing manufacturer stock formula and only adjust fragrance or minor cosmetic tweaks, the fee may be $0–$500. Stability testing: a 12-week accelerated stability study runs $800–$1,500 at most contract labs. Some manufacturers include basic stability in their development package; others bill separately. Challenge testing (preservative efficacy testing) is an additional $300–$600. Shipping and 3PL: if you're using a third-party logistics provider, factor in inbound freight from the manufacturer ($0.10–$0.40 per unit depending on distance) plus 3PL receiving and storage fees. A realistic all-in launch budget for a 500-unit pilot run of a private label TXA + SA body serum, including development, stability, packaging, fill, and label, is $5,500–$10,000. AJ Cosmo Labs connects you with manufacturers who can provide itemized quotes so you know exactly what you're paying for before you commit.

For a leave-on body brightening serum, the cosmetic industry standard for tranexamic acid concentration is 1% to 3%, with most commercial formulas landing at 2% as a balance between efficacy, stability, and cost. Here is the rationale for that range. Tranexamic acid works by inhibiting the interaction between keratinocytes and melanocytes that triggers melanin production, specifically by blocking plasminogen activator and reducing prostaglandin synthesis. Published clinical studies on facial hyperpigmentation — the primary research base, as body-specific TXA studies are less abundant — have demonstrated measurable brightening at concentrations as low as 2%, applied topically twice daily over 8–12 weeks. At concentrations below 1%, the evidence for meaningful skin brightening is weak and largely anecdotal. Above 3%, you see diminishing returns on efficacy, and raw material cost rises without a proportional consumer benefit. For body serums specifically, there is one formulation consideration that differs from facial serums: the total surface area being treated is much larger, meaning consumers apply more product per use. This can make higher-concentration formulas feel more expensive to use and can increase the risk of mild irritation when TXA is combined with salicylic acid, which adds its own low-level exfoliant activity. For this reason, many formulators recommend starting at 1.5–2% TXA in a body serum rather than going straight to 3%. Transexamic acid is water-soluble and incorporates well into aqueous serums at these concentrations. It is generally stable at pH 4.0–7.0, which overlaps acceptably — though not perfectly — with the optimal pH for salicylic acid efficacy (3.0–4.0). A skilled cosmetic chemist will typically buffer the formula at pH 3.8–4.2 to satisfy both actives reasonably well, then run stability data to confirm no degradation of either over a 12-week accelerated test. One mistake founders make is selecting a very high TXA concentration — 3%+ — based on the assumption that more active equals more differentiation in marketing. While a 3% TXA claim is compelling, it does not guarantee better consumer outcomes if the formula pH, delivery system, or skin contact time are suboptimal. A well-stabilized 2% formula with a good humectant base and no competing irritants will often outperform a poorly stabilized 3% formula on consumer skin feel and repeat purchase. For regulatory purposes, tranexamic acid at cosmetic concentrations (1–3%) is classified as a cosmetic ingredient in both the US and EU and carries no special restrictions. It does not trigger OTC drug status. Your product's regulatory complexity is driven by the salicylic acid component and your label claims, not the TXA level. When you post your product brief on AJ Cosmo Labs, including your target TXA and SA concentrations upfront helps manufacturers respond with accurate quotes rather than placeholders.

Finding a vetted low-MOQ cosmetic contract manufacturer for a technically complex body serum requires more than a Google search and a round of cold emails. Here is a practical step-by-step approach that experienced indie founders use. Step 1: Write a tight product brief before you contact anyone. Your brief should specify the actives and target concentrations (e.g., 2% TXA, 1.5% SA), your target pH range, desired fill size, packaging type (pump, dropper, airless), preferred MOQ, target unit cost, and your timeline. A vague inquiry — 'I want a brightening serum' — gets you generic responses. A specific brief gets you real quotes. Step 2: Identify manufacturers who specialize in active-ingredient formulation, not just commodity private label. Many private label houses offer generic, stock brightening serums that do not hit efficacious TXA concentrations or don't have the pH control competency to combine TXA and SA in one stable formula. Ask directly: 'Can you show me a batch record or COA for a finished formula containing both tranexamic acid and salicylic acid?' If they cannot produce documentation, move on. Step 3: Verify GMP compliance. For a US-market cosmetic, ask if the facility follows ISO 22716 Cosmetic GMP guidelines. For an OTC-positioned product (if your SA is at 2% with acne claims), the facility must comply with pharmaceutical cGMPs under 21 CFR Parts 210/211, which is a significantly higher bar. Request their most recent third-party audit summary. Step 4: Ask about stability and safety testing infrastructure. A manufacturer who cannot run accelerated stability in-house (or doesn't have a preferred external lab) will slow your development timeline and may leave you with a formula that degrades on shelf. Ask specifically about preservative efficacy testing (challenge testing) for a water-based serum — this is non-negotiable. Step 5: Get itemized quotes from at least three suppliers. Compare not just the per-unit price but what is included: formula development fee, stability testing, label application, outbound inspection, and minimum order flexibility for reorders. Step 6: Request a sample run or pilot batch before committing to full production. Most reputable low-MOQ manufacturers will offer a lab sample (5–10 units) or a small pilot batch (25–50 units) for an additional fee. This lets you evaluate the product before spending thousands on a full run. The biggest time-waster in this process is the sequential discovery model — contacting one manufacturer, waiting for a response, discovering a MOQ mismatch, then starting over. AJ Cosmo Labs eliminates this by letting you post one brief on the iOS app and receive inbound responses from multiple vetted cosmetic contract manufacturers simultaneously. You can compare capabilities, MOQs, and preliminary quotes side by side, message suppliers directly, track sample shipments, and manage milestone payments — all inside the app. Download AJ Cosmo Labs from the App Store and post your brief today to start receiving manufacturer responses within days rather than weeks.

Yes, tranexamic acid and salicylic acid can be combined in the same body serum formula, and this combination is increasingly common in the hyperpigmentation-plus-exfoliation positioning that drives the body brightening serum category. However, combining them requires careful formulation work to balance the competing stability requirements of both actives. The core challenge is pH. Salicylic acid is most effective — and most stable — at a pH of roughly 3.0–4.0. Below pH 3, the formula becomes too acidic for comfortable leave-on body application and risks irritation. Above pH 4.5, salicylic acid begins to lose its exfoliant efficacy as more of it converts to the ionized salicylate form, which does not penetrate the skin lipid barrier as readily. Tranexamic acid, by contrast, is stable across a broader pH range (4.0–7.0) and is chemically non-reactive with salicylic acid — there is no known compatibility issue or reaction between the two molecules. In practice, a skilled cosmetic chemist will buffer the combined formula at pH 3.8–4.2. At this pH, salicylic acid retains meaningful exfoliant activity, tranexamic acid is stable, and the formula is tolerable for twice-daily body application on most skin types. Sensitive skin consumers may experience mild tingling, which can be mitigated by including a humectant-rich base — glycerin at 3–5%, or hyaluronic acid at 0.1–1% — and by keeping SA at the lower end of the efficacy range (0.5–1.5%) when combining with TXA. Preservation is the other formulation challenge. A water-based serum at pH below 4.5 with two actives has a complex microbial environment. Standard broad-spectrum preservatives like phenoxyethanol (at 0.5–1%), ethylhexylglycerin, or sodium benzoate are commonly used in this pH range. Challenge testing to USP 51 or EU Ph. Eur. 5.1.3 criteria is essential before launch — do not rely on a manufacturer's assurance alone. From a consumer efficacy standpoint, the combination is well-motivated. Salicylic acid's exfoliant activity increases cell turnover and removes the surface layer of dead skin cells that can dull complexion and impede active penetration. This creates a receptive skin surface for tranexamic acid to work on the underlying melanin-transfer pathways. Many cosmetic chemists describe SA as a 'prep' active that amplifies the brightening effect of TXA, though clinical body-specific data on this combination remains limited compared to the stronger facial hyperpigmentation literature. For private label founders, the key sourcing implication is that not every contract manufacturer has the formulation competency to build a stable, efficacious TXA + SA body serum. When evaluating suppliers through AJ Cosmo Labs or any sourcing channel, require documentation of pH stability across a minimum 12-week accelerated stability study before approving a formula for production.